Piperacillin is a penicillin antibiotic combined with tazobactam to treat piperacillin-resistant, piperacillin/tazobactam susceptible, β-lactamase generating strains of several bacteria. Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections.
- Mechanism
- Curator reviewed
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Piperacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Piperacillin interferes with an autolysin inhibitor.
- Primary indication
- For the treatment of polymicrobial infections.Curator reviewed · 16 structured indications
- Formula / weight
- C23H27N5O7S · 517.555 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1993
- Also known as
- Piperacillina
- Code names
- BL-P 1908 · CI 867 · CL 227193 · T 1220
- Brand names
Resolves to
IVBHGBMCVLDMKU-GXNBUGAJSA-NSMILES[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Piperacillin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account